Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.91), in-line with the analyst estimate of ($0.91). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $7.55 million.

"The past quarter and recent period were marked by tremendous progress in our efforts to advance innovative medicines to patients. Notably, we made significant progress with our late-stage clinical programs, including new data on patisiran and revusiran. Importantly, we’re on track to complete enrollment in our APOLLO Phase 3 trial of patisiran within the next three to four months; if the study is positive, APOLLO data are expected to support an NDA submission in 2017,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “Overall, we believe our new clinical data confirm the reproducible and modular characteristics of our platform with all six programs for which we’ve reported human data to date showing positive target gene knockdown results and associated clinical pharmacology. As we enter the final months of 2015, we look forward to additional important data read outs at AHA and ASH and an in depth review of our pipeline at our R&D Day.”

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.